B
TEVA icon

Barings’s Teva Pharmaceuticals TEVA Stock Holding History

Barings’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,565
Closed -$286K – 754
2018
Q4 		$286K Sell
18,565
-15,289
-45% -$313K 0.01% 602
2018
Q3 		$730K Buy
+33,854
New +$786K 0.01% 545
2016
Q2 		– Sell
-4,100
Closed -$219K – 960
2016
Q1 		$219K Sell
4,100
-2,900
-41% -$170K 0.01% 872
2015
Q4 		$459K Hold
7,000
– – 0.01% 675
2015
Q3 		$395K Hold
7,000
– – 0.01% 691
2015
Q2 		$414K Buy
+7,000
New +$432K 0.01% 743

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barings's TEVA Position: Q1 2019 in Review

Barings sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 18,565 shares — an estimated $286K sold.

Barings first reported a position in TEVA in Q2 2015 and held it in 6 quarters. The position peaked at $730K in Q3 2018. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Barings reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Barings sold 18,565 Teva Pharmaceuticals shares in Q1 2019, an estimated $286K.
  • Barings first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Barings's Teva Pharmaceuticals position peaked at $730K in Q3 2018.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Barings's 13F filing for Q1 2019, filed 8 May 2019.